ABBIOSCI INC

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.

Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).

In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.

For more information, visit www.anaptysbio.com.

💡 A biotechnology group based on complementary expertise with multidisciplinary know-how

Custom Products & Services delivering a range of integrated biotechnology solutions 🤝

🏢 COMPANIES:

- RD-Biotech SAS (www.rd-biotech.com):
Custom services, Biomanufacturing and purification (monoclonal antibodies, recombinant proteins, plasmids, cells), hybridoma development, expression vectors, transfection, antibody sequencing, chimerization and humanization, analytical services and FastELISA kits for Immunoglobulins quantification and cellular contaminants detection.

- SYnAbs (www.synabs.be):
Primary and Secondary Antibodies Anti-species, Isotype controls, custom services, hybridoma development – rat, guinea pig, murine, Immunoassays

- QVQ (www.qvquality.com)
VHH Phage display services and a large range of VHH products

- Smaltis (www.smaltis.fr)
CRO specialized in microbiology, an high expertise in the fileds of antibiotic resistance, microbiota and strain engineering. Custom services and a large collection of genetically modified bacterial strains.

📈 EFFECTIVE SYNERGY

As part of a team of experts to ensure:
- The development of new biological tools in immunology, molecular biology, cellular engineering
- Identification of new markers
- The development of analytical methods
- Scientific and technical support
- The quality of services and products developed and manufactured in-house

✔ MAIN SECTORS OF ACTIVITY

- Pharmaceutical
- BioTherapeutics
- Biotechnology
- In vitro diagnostics
- Animal health
- Dermo-cosmetic
- Agribusiness
- Life sciences
- Environment
- Research Institutes

PathoQuest, spin out of Institut Pasteur, is a genomic expert company offering a game-changing next-generation sequencing (NGS) platform for microbiology testing.
The company has developed 2 applications:
• The QC of biological drugs (ATMP, Vaccines, antibodies…) allowing robust and fast analysis under GLP grade.
• The diagnosis of bloodstream Infections (including sepsis) directly from blood.
PathoQuest’s technology combines proprietary sample preparation protocols, applicable to several types of biological samples with proprietary pathogen genome sequence databases and automated analysis pipelines.

BIOLOGICS TESTING OFFER
PathoQuest offers Biotech and biopharmaceutical companies GLP grade solutions to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and, recombinants by preventing adventitious agent contamination and cell-line misidentification.
Advanced NGS-based solutions supplement or replace traditional testing methods and support the strategic decision-making process allowing for a robust and unambiguous level of testing and faster turnaround time.
Based in Paris, France, PathoQuest has established a U.S. subsidiary and is expanding its capabilities by implementing a state-of-the-art testing facility at its location near Philadelphia. The company has also signed in 2018 a strategic partnership with Charles River Lab (Boston, USA)

DIAGNOSIS OF BLOODSTREAM INFECTIONS
- PathoQuest has developed iDTECT® Blood Test, the first and only clinical CE In Vitro Diagnostic (IVD) metagenomic test for infectious diseases.
- The test provides directly from blood to clinicians and microbiologists an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test is designed to improve antibiotic stewardship and lead to better patient care through personalized treatment.

For more information about PathoQuest, feel free to reach out!

Hangzhou AllTest Biotech Co., Ltd is located in 550#，Yinhai Street, Baiyang District, Hangzhou Economic-Technological Development Area, the company registered capital of 15 million RMB. The company’s total construction area is about 3200 M2. The company holds strong ability of scientific research and innovative technology. AllTest Biotech leads the development frontier of biological technologies such as monoclonal antibody-colloidal gold and latex technique, gene engineering, compound antigen and immunoassay.

AllTest Biotech is thriving on design, development, manufacturing and sales of the lateral flow rapid IVD products and food safety test product. The product is broadly recognized in the international market for its rapid, convenience and accurateness. AllTest Biotech will strive to become the leader and pioneer in the diagnostic industry field of China and the world.

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging